New research published in Proceedings of the National Academy of Sciences USA has shown that a connexin hemichannel inhibitor, D4, has therapeutic potential in the pilocarpine mouse model of temporal lobe epilepsy (TLE). The findings suggest that treatment with D4 attenuates seizures by reducing neuroinflammation.